Phage Futures Europe 2022

The leading platform accelerating the translation of bacteriophages into clinically and commercially viable therapeutics and tangible commercial solutions

VIEW THE 2022 AGENDA
Amsterdam, Netherlands
6-7 July, 2022

“I thought the meeting was well put together with a good variety of presenters from academia, government, and industry. I would encourage other phage experts to attend future meetings.”

Catherine Loc-Carrillo, University of Utah

As a preview ahead of Phage Futures Europe, take a look at the attendee list from the last Phage Futures Europe in November 2021.

Why Attend

Join us at the international Phage Futures Congress 2022 as we create a stage upon which to initiate all-important discussions and forge partnerships between key stakeholders from all over the world. Experts in their respective fields will discuss how to translate new phage-based applications into clinical studies & beyond.

Discover how you can be at the forefront of the developing phage therapy market and build your next phage product to target various animal health and agriculture markets. Network & learn from established biotech companies, emerging start-ups, leading academics, global accelerator representatives, investment firms, international healthcare organisations and regulatory bodies.

Expect to hear & participate in:

  • Advice on how to successfully navigate clinical trial progression to prove efficacy along with recent developments from leading biotechs in phage-based application
  • Regulatory discussions between international governing bodies with exclusive follow-up conversations with the experts
  • Progressive talks on how CMOs can improve & participate in furthering the phage therapy market
  • Insights into emerging markets for phage application, such as oncology, diagnostics & microbial gene therapy

TALK TO OUR SPEAKERS ABOUT...

1. How to design a successful phage clinical trial

2. How to manipulate the microbiome with phage therapy to treat chronic diseases

3. The implications and safety requirements of administering phage therapy to patients

4. What indications are suitable for phage therapy within Europe?

5. How to obtain broad phage host range and maintain synergy within a fixed cocktail

6. Applications of phage related products as an alternative strategy to access the market 

7. How magistral preparative supports the personalised medicine method

8. The route to appropriate clinical data: through innovative trial design

9. How to alleviate future multi-drug resistance through phage evolution research

10. What are the commercial pathways for phage therapies?

2022 Advisory Board

Author:

Dr Gina Suh

Infectious Disease Specialist
Mayo Clinic

Dr Gina Suh

Infectious Disease Specialist
Mayo Clinic

Author:

Dr Todd Black

Executive Director of Infectious Diseases/Vaccines
Merck

Dr Todd Black

Executive Director of Infectious Diseases/Vaccines
Merck

Author:

Jessica Sacher

Co-Founder
Phage Directory

Jessica Sacher

Co-Founder
Phage Directory

Author:

Sandra Giannini

Director
GSK

Sandra Giannini

Director
GSK

Author:

Ruby Lin

Deputy Director of Phage, Australia
The Westmead Institute

Ruby Lin

Deputy Director of Phage, Australia
The Westmead Institute

Who Will Be There

10%
Regulatory / Government
10%
Service Providers
5%
Physicians / Clinicians
30%
Biotechs
15%
Multinationals
30%
Academics

Regulatory / Government

Service Providers

Physicians / Clinicians

Biotechs

Multinationals

Academics

POSTER SESSION

Looking to showcase your recent work to the phage therapy community?

Our dedicated poster session is the perfect way to get your research noticed. Ideal for PhD students or Post-Doctoral researchers.

In order to present a poster at the forum you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration). At the congress, your presentation will be displayed in a dedicated poster area. 

By submitting, you are also eligible for €100 off the academic rate.

Apply to submit your poster here. The submission deadline is 13 May 2022.



2022 SPEAKERS

 

Dr Peter Beyer

Unit Head, Antimicrobial Resistance Division
WHO

Peter Beyer, a trained lawyer, is a Senior Advisor with the World Health Organization (WHO) in Geneva where he leads a team working on global initiatives on antimicrobial resistance. He focuses on developing global instruments to combat antimicrobial resistance and to foster the development of new antimicrobial treatments.

Dr Peter Beyer

Unit Head, Antimicrobial Resistance Division
WHO

Dr Peter Beyer

Unit Head, Antimicrobial Resistance Division
WHO

Peter Beyer, a trained lawyer, is a Senior Advisor with the World Health Organization (WHO) in Geneva where he leads a team working on global initiatives on antimicrobial resistance. He focuses on developing global instruments to combat antimicrobial resistance and to foster the development of new antimicrobial treatments. Peter was instrumental in setting up the Global Antibiotic R&D Partnership (GARDP), a foundation that is developing new antibacterial treatments as well as the trilateral collaboration among the World Intellectual Property Organization (WIPO), the World Trade Organization (WTO) and WHO. Previously, Peter Beyer was a Legal Advisor to the Swiss Federal Institute of Intellectual Property in Berne. He negotiated bilateral free trade agreements for the European Free Trade Association (EFTA) and was responsible for the bilateral dialogue between Switzerland and China on intellectual property. Prior to joining the Swiss civil service, Peter Beyer worked with the Ecologic Institute in Berlin on environmental law and policy.

 

Dr Gina Suh

Infectious Disease Specialist
Mayo Clinic

Dr Gina Suh

Infectious Disease Specialist
Mayo Clinic

Dr Gina Suh

Infectious Disease Specialist
Mayo Clinic
 

Dr. Jean-Paul Pirnay

Head of the Laboratory for Molecular and Cellular Technology
Queen Astrid Military Hospital

Dr. Jean-Paul Pirnay

Head of the Laboratory for Molecular and Cellular Technology
Queen Astrid Military Hospital

Dr. Jean-Paul Pirnay

Head of the Laboratory for Molecular and Cellular Technology
Queen Astrid Military Hospital
 

Tobi Nagel

Founder
Phages for Global Health

Tobi Nagel

Founder
Phages for Global Health

Tobi Nagel

Founder
Phages for Global Health
 

Dr Danish Malik

Reader in Industrial Biotechnology
Loughborough University

Dr Danish Malik

Reader in Industrial Biotechnology
Loughborough University

Dr Danish Malik

Reader in Industrial Biotechnology
Loughborough University
 

Matthew Tebeau

Chief Operating Officer
Proteon Pharmaceuticals SA

Matthew Tebeau

Chief Operating Officer
Proteon Pharmaceuticals SA

Matthew Tebeau

Chief Operating Officer
Proteon Pharmaceuticals SA
 

Olivia McAuliffe

Research Officer
Teagasc Food Research Centre

Olivia McAuliffe

Research Officer
Teagasc Food Research Centre

Olivia McAuliffe

Research Officer
Teagasc Food Research Centre
 

Dr. Edith Hessel

CSO
Eligo Bioscience

Dr. Edith Hessel

CSO
Eligo Bioscience

Dr. Edith Hessel

CSO
Eligo Bioscience
 

Dr Cara Fiore

Senior Regulatory Reviewer, Microbiologist
FDA

Dr Cara Fiore

Senior Regulatory Reviewer, Microbiologist
FDA

Dr Cara Fiore

Senior Regulatory Reviewer, Microbiologist
FDA
 

Ruby Lin

Deputy Director of Phage, Australia
The Westmead Institute

Ruby Lin

Deputy Director of Phage, Australia
The Westmead Institute

Ruby Lin

Deputy Director of Phage, Australia
The Westmead Institute
 

Merav Bassan

Chief Development Officer
BiomX

Dr. Bassan was most recently Vice President Head of Translational Sciences at Teva Pharmaceutical Industries, Inc., where she was responsible for early stages of clinical development via translation from animal data to human. Prior to this role, Dr. Bassan served as Vice President of Project Leadership at Teva Pharmaceutical, where she managed project leaders overseeing end-to-end drug development at pre-clinical, PI-III and post marketing stages in multiple therapeutic areas, such as pain, oncology, women‘s health, endocrinology, GI, biosimilars and other areas. Overall, Dr.

Merav Bassan

Chief Development Officer
BiomX

Merav Bassan

Chief Development Officer
BiomX

Dr. Bassan was most recently Vice President Head of Translational Sciences at Teva Pharmaceutical Industries, Inc., where she was responsible for early stages of clinical development via translation from animal data to human. Prior to this role, Dr. Bassan served as Vice President of Project Leadership at Teva Pharmaceutical, where she managed project leaders overseeing end-to-end drug development at pre-clinical, PI-III and post marketing stages in multiple therapeutic areas, such as pain, oncology, women‘s health, endocrinology, GI, biosimilars and other areas. Overall, Dr. Bassan has over 20 years of leadership experience with clinical and drug development teams in her various roles at Teva Pharmaceutical and other smaller biotech companies. Dr. Bassan is also a member of the Israeli 8400 health network, a cross-sector network of leaders actualizing the global disruptive capabilities of Israel’s HealthTech ecosystem. Dr. Bassan holds a Ph.D. in Neuroscience from the Tel-Aviv University Sackler School of Medicine and completed a post-doctoral fellowship in Neuroscience at Harvard University.

 

Sofia Corte-Real

Scientific Advisor
Technophage

Sofia Corte-Real

Scientific Advisor
Technophage

Sofia Corte-Real

Scientific Advisor
Technophage
 

Christian Röhrig

Director of Operations
Micreos

Christian Röhrig

Director of Operations
Micreos

Christian Röhrig

Director of Operations
Micreos
 

Alexander Sulakvelidze

President & CEO
Intralytix

Dr. Alexander “Sandro” Sulakvelidze, Ph.D. is the President and CEO of Intralytix.  He is an internationally recognized expert in phage technology who was instrumental in securing the first ever FDA-approval for phage-based food safety product in the World. Dr. Sulakvelidze has published extensively on the subject of phage therapy and biocontrol, including co-editing a major book about bacteriophages entitled “Bacteriophages: Biology and Applications”. He is the author of 15 issued and several pending patents in the field of bacteriophage technology. 

Alexander Sulakvelidze

President & CEO
Intralytix

Alexander Sulakvelidze

President & CEO
Intralytix

Dr. Alexander “Sandro” Sulakvelidze, Ph.D. is the President and CEO of Intralytix.  He is an internationally recognized expert in phage technology who was instrumental in securing the first ever FDA-approval for phage-based food safety product in the World. Dr. Sulakvelidze has published extensively on the subject of phage therapy and biocontrol, including co-editing a major book about bacteriophages entitled “Bacteriophages: Biology and Applications”. He is the author of 15 issued and several pending patents in the field of bacteriophage technology. 

 

Nancy Tawil

Chief Scientific Officer
Phagelux

Nancy Tawil, Mcb.A, M. Eng, Ph.D., is the Chief Scientific Officer at Phagelux Inc. and a Professor of Biomedical Engineering at Polytechnique Montreal where she oversees scientific research, product development, and clinical strategy.  Her research focuses on the development of novel heterofunctional materials and anti-infective treatments for multi-drug resistant infections. Her expertise and interests include drug delivery, phage science, polymer chemistry, and novel combination devices. Dr.

Nancy Tawil

Chief Scientific Officer
Phagelux

Nancy Tawil

Chief Scientific Officer
Phagelux

Nancy Tawil, Mcb.A, M. Eng, Ph.D., is the Chief Scientific Officer at Phagelux Inc. and a Professor of Biomedical Engineering at Polytechnique Montreal where she oversees scientific research, product development, and clinical strategy.  Her research focuses on the development of novel heterofunctional materials and anti-infective treatments for multi-drug resistant infections. Her expertise and interests include drug delivery, phage science, polymer chemistry, and novel combination devices. Dr. Tawil has over 15 years in phage research experience and is named inventor on multiple patents that aim to bridge the gap between phage science and technology.

 

Felipe Molina PhD

Professor
University of Extremadura

My research is focused on bacterial genetics, the cell cycle of microorganisms and phages as biocontrol agents in dairy products.

Felipe Molina PhD

Professor
University of Extremadura

Felipe Molina PhD

Professor
University of Extremadura

My research is focused on bacterial genetics, the cell cycle of microorganisms and phages as biocontrol agents in dairy products.

 

Dr Minmin Yen

CEO & Co-Founder
PhagePro

Dr. Yen is a 2018 MIT Technology Review Innovator Under 35 and a microbiologist with a global health and program management background. Since co-founding PhagePro, Dr. Yen has received numerous awards and won several startup competitions recognizing her innovative leadership in global health, such as the ASTMH Innovations Pitch Competition and LaunchBio's The Big Pitch.

Dr Minmin Yen

CEO & Co-Founder
PhagePro

Dr Minmin Yen

CEO & Co-Founder
PhagePro

Dr. Yen is a 2018 MIT Technology Review Innovator Under 35 and a microbiologist with a global health and program management background. Since co-founding PhagePro, Dr. Yen has received numerous awards and won several startup competitions recognizing her innovative leadership in global health, such as the ASTMH Innovations Pitch Competition and LaunchBio's The Big Pitch. She has been selected for several fellowships, including the MassNextGen Fellowship for women-led early-stage life science businesses, The Capital Network Female Founder Fellowship, and the Henri Termeer Legacy Program. An advocate for DEI in both biotech and global health communities, Dr. Yen strives to center the voices and the needs of the most marginalized.

 

Paul Garofolo

CEO
Locus Biosciences

Paul Garofolo

CEO
Locus Biosciences

Paul Garofolo

CEO
Locus Biosciences
 

Lorenz Leitner

Neuro-urologist
Balgrist University

Lorenz Leitner

Neuro-urologist
Balgrist University

Lorenz Leitner

Neuro-urologist
Balgrist University
 

Kristin Wannerberger

Director R&D Alliance Management
Ferring Pharmaceuticals

Kristin holds a Ph.D. in Biophysical Technology from Lund University, Sweden and a M.Sc. Chem. Eng. - Food and Dairy Technology. Kristin has more than 20 years of experience of Pharmaceutical Industry working with development of drugs covering various therapeutical areas and several administration forms. She has had various positions based in Sweden, Denmark and Switzerland and currently holds a position as Director Alliance Management R&D, based in Switzerland. She is directing several alliances in the field of the human microbiota/microbiome.

Kristin Wannerberger

Director R&D Alliance Management
Ferring Pharmaceuticals

Kristin Wannerberger

Director R&D Alliance Management
Ferring Pharmaceuticals

Kristin holds a Ph.D. in Biophysical Technology from Lund University, Sweden and a M.Sc. Chem. Eng. - Food and Dairy Technology. Kristin has more than 20 years of experience of Pharmaceutical Industry working with development of drugs covering various therapeutical areas and several administration forms. She has had various positions based in Sweden, Denmark and Switzerland and currently holds a position as Director Alliance Management R&D, based in Switzerland. She is directing several alliances in the field of the human microbiota/microbiome.

DOWNLOAD THE AGENDA

The Phage Futures Europe 2022 agenda is here! Here's what to expect:

  • 200+ participants from academic, industry, biotech and regulatory bodies onsite
  • European and global phage thought leaders on the speaking agenda and ready to answer your big questions
  • 2 days of furthering phage therapy

"First conference really focused on moving phage therapy and phage-related technologies forward. A great combination of regulatory, commercial, and scientific presentations." – Shawna McCallin, Phage Forward


Download 2022 Europe Agenda

2022 Partners

GMP Partner

Event Partners

Innovation Partner

Lead Media Partner

Media Partners

Past attendees

TESTIMONIALS

Partner With Us

Based on your objectives, we can create bespoke packages designed specifically for you – from presenting your expertise on the main stage, to hosting a private dinner. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking.

To discuss your objectives and partnership opportunities please contact Ryan Sanderson, Commercial Partnerships Director at [email protected].

Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact Laura Hobson, Senior Marketing Manager; [email protected]

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:

Registration ends in

Saturday, June 11, 2022 to Friday, July 8, 2022
Tier 1 - Academics
€1,099
A teacher or scholar in a University or other institute of Higher Education
Saturday, June 11, 2022 to Friday, July 8, 2022
Tier 2 - Biotech, Pharma & Investors
€1,999
Saturday, June 11, 2022 to Friday, July 8, 2022
Tier 3 - Service Providers
€3,399
Sequencers, CROs, CDMOs, Ingredient companies, Consultants
Preparing registration...

Venue

Hotel Okura Amsterdam, Ferdinand Bolstraat 333, 1072 LH Amsterdam, Netherlands

We're excited to welcome you face-to-face in Amsterdam! 

Click here to view local hotels.

Returning Safely Measures

Whether sponsors, speakers or attendees, our customers attend Kisaco Research events to connect, learn and innovate to know more and do business. It is our commitment that as we return to in-person events, they can do this effectively, safely and with confidence.

All in-person Kisaco Research events will prioritize the health and safety of colleagues and customers and, in the first instance, will be run in accordance with official government and local authority guidance, as well as any venue or location-specific regulations.

Kisaco Research is committed to following the Association of Event Organisers All Secure Standard, which has been approved by by UK Government.

Download the Kisaco Research Returning Safely Measures 

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us